Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170204 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
- 20
- Study locations
NCT05170204 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 71 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05170204, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Alectinib
- DRUG Entrectinib
Study Locations (20)
Other
- UZ Gent - Ghent
- RedSalud Vitacura - Santiago
- Hunan Cancer Hospital - Changsha
- Xinqiao Hospital of Third Military Medical University - Chongqing
- Shandong Cancer Hospital - Jinan
- Shanghai Pulmonary Hospital - Shanghai
- Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo - Bogota, D.C.
- Hospital Universitario San Ignacio - Bogotá
- Centre Francois Baclesse - Caen
- Centre Leon Berard - Lyon
- Hopital Nord - Marseille
- Helios Klinikum Emil von Behring GmbH - Berlin
São Paulo
- Hospital de Cancer de Barretos - Barretos
- Instituto do Cancer do Estado de Sao Paulo - ICESP - São Paulo
Oregon
- Northwest Cancer Specialists, P.C. - Tigard
Pennsylvania
- Hillman Cancer Center - Pittsburgh
Victoria
- Peter MacCallum Cancer Centre - Melbourne
Western Australia
- One Clinical Research - Nedlands
Emilia-Romagna
- IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola - Meldola
Lombardy
- Asst Grande Ospedale Metropolitano Niguarda - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2030-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05170204
The ClinicalTrials.gov registry entry for NCT05170204 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT05170204 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, São Paulo, Oregon.
Frequently Asked Questions
What is clinical trial NCT05170204 about?
NCT05170204 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)". This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
What is the current status of trial NCT05170204?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2022-11-01. Estimated completion is 2030-06-19.
What conditions does trial NCT05170204 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05170204?
The interventions under investigation include: Durvalumab (DRUG), Alectinib (DRUG), Entrectinib (DRUG).
Who is sponsoring clinical trial NCT05170204?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05170204 being conducted?
This trial has 20 study locations across Oregon, Pennsylvania, Victoria, Western Australia, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.